For several years now, researchers have been aware of important links between cholesterol and Alzheimer's disease. A new study by Dr. Dora Kovacs and her team at Massachusetts General Hospital brings us one step closer to a potential drug that could interrupt the disease process.
On May 18 Jeff Morby, chairman and co-founder of Cure Alzheimer’s Fund, was honored with the prestigious Paul Harris Award from Rotary District 7950. Paul Harris founded the Rotary Club more than a century ago and the award was created to recognize those who have made great contributions to society under the Rotary’s motto of “Service Above Self.”
An innovative new public/private collaboration between Cure Alzheimer’s Fund and the National Institute of Mental Health (NIMH) already has started to bear fruit.
SAN DIEGO, July 16, 2013 – Confirming an enzyme in the serine hyrdrolase family as a therapeutic target to slow and potentially reverse the effects of Down syndrome and Alzheimer’s disease is the goal of new research announced today by Abide Therapeutics, in collaboration with researchers at the University of California, San Diego School of Medicine and funded by a grant from the Cure Alzheimer’s Fund.
BOSTON – New research examining levels of the hallmark proteins linked to Alzheimer's disease found in patients suffering from post-operative cognitive changes (POCC) may lead to safer surgery care and better post-operative outcomes for senior adults.
Research uncovering 12 new gene variations connected to the cause of the early-onset familial form of Alzheimer’s disease (EO-FAD), which generally strikes before the age of 65, is being published in the journal Molecular Psychiatry.
In his heyday, Professor Charles K. Kao was a pioneer in the field of fiber optics. In 2009 he was honored with the Nobel Prize in Physics. Today, at age 79, Kao no longer is able to read or speak, because he suffers from Alzheimer’s disease.
As hard as life is for Gwen Kao, his wife for more than 50 years and primary caregiver, she created The Charles K. Kao Foundation in his honor to raise awareness for the disease and educate the public about what can be done.
While many were anxious to accept initial findings showing a drug known as Targretin’s “too good to be true” lab results with Alzheimer’s disease, subsequent attempts to confirm and replicate the original data regarding the ability of Targretin to remove amyloid plaques, the cardinal lesion of the disease, have largely failed. Cure Alzheimer’s Fund Research Consortium members Dr. Sangram Sisodia, professor of neuroscience at the University of Chicago and Dr.
Cure Alzheimer’s Fund and National Institute of Mental Health Join in Awarding Millions for Whole Genome Sequencing
Henry McCance, chairman emeritus of Greylock Partners, co-founded Cure Alzheimer’s Fund (CAF) in 2005 after getting frustrated with the lack of knowledge about the disease when his wife was diagnosed. He was interviewed by the Boston Business Journal about his venture capital approach to funding Alzheimer's disease research.
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.